US Government and Ebola

Covid-19 Update

Find out more

Covid-19 Update

Please be reassured that Franks & Co Limited have taken contingency measures to ensure that the firm will continue to operate without any disruption in our services in view of the COVID-19 global pandemic.

Our attorneys and support staff are equipped to work remotely to handle matters reliably and with our usually precision and efficacy. All remote working will be conducted via virtual private networking to maintain client’s data security and confidentiality. Our normal operating hours will continue.

We extend our well wishes to all at these difficult times.

Skip navigation

The WHO is searching for means by which it can prevent the spread of Ebola and allow the production of experimental vaccines on a larger scale.

The Ebola virus was discovered by the Belgian Scientist Peter Piot in 1976. However, a small study of the patent literature shows that it is not Peter Piot but the US government that has an impressive portfolio relating to the Ebola virus sequences and antibodies which bind to Ebola proteins for use as a possible vaccine therapy.

The US patent 6,630,144B in the name of the United States Army Medical Research Institute of Infectious Diseases, describes a mixture of antibodies against Ebola.

European Patent EP 1 608 393B, also in name of the US Army describes several Ebola peptides which can be used for the generation of a vaccine.

Vanda Pichova previously worked as one of two European Patent Attorneys in the patents department of Innogenetics in Belgium, prior to joining Franks & Co.

Article Published October 8, 2014